Disease · MONDO_0000432

lymphoplasmacytic lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. lymphoplasmacytic lymphoma. Diseases, record MONDO_0000432. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000432

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: lymphoplasmacytic lymphoma; Open Targets
Open Targets ID: MONDO_0000432; Open Targets
Other names: Immunocytoma, lymphoplasmacytic type, lymphoma, lymphoplasmacytic, malignant, lymphoma, plasmacytic, lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia), lymphoplasmacytoid lymphoma; Open Targets
Disease Ontology: DOID:0050747; Disease Ontology
NCI Thesaurus: C3212; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 30 drugs, from PMDA; Open Targets

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ZANUBRUTINIB	CHEMBL3936761	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
CHLORAMBUCIL	CHEMBL515	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUDARABINE PHOSPHATE	CHEMBL1096882	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
MITOXANTRONE	CHEMBL58	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BORTEZOMIB	CHEMBL325041	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
VENETOCLAX	CHEMBL3137309	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 30

See all 30 drugs

Targets89

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
BTK	Tyrosine-protein kinase BTK	4	Tyrosine-protein kinase BTK inhibitor	Approval	https://conductscience.org/library/genes/695	Drugs and targets
ADRM1	26S proteasome	2	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/11047	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/1642	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	2	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
PIK3CD	PI3-kinase class I	2	PI3-kinase class I inhibitor; PI3-kinase p110-delta subunit inhibitor	Phase 2	https://conductscience.org/library/genes/5293	Drugs and targets
PSMA1	26S proteasome	2	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5682	Drugs and targets
PSMA2	26S proteasome	2	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5683	Drugs and targets
PSMA3	26S proteasome	2	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5684	Drugs and targets

1 to 10 of 89

See all 89 targets

Trials27

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01799889	Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies	Phase 2	326	2020-09-23	Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Non-FL Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma	ENTOSPLETINIB	Its record names the disease	ClinicalTrials.gov
NCT01076543	Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	Phase 1/2	110	2019-10-16	AIDS-Related Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Waldenstrom Macroglobulinemia	LENALIDOMIDE, TEMSIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT03779113	An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma	Phase 1	69	2026-02-18	Non Hodgkin Lymphoma	SOVLEPLENIB	Its record names the disease	ClinicalTrials.gov
NCT01796470	Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies	Phase 2	66	2020-06-02	Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin's Lymphoma	ENTOSPLETINIB, IDELALISIB	Its record names the disease	ClinicalTrials.gov
NCT01294579	Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)	Phase 2	49	2018-08-09	Lymphoma, Non-Hodgkin	BENDAMUSTINE, OFATUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00784927	Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma	Phase 2	36	2016-02-08	Lymphoma	CYCLOPHOSPHAMIDE, DEXAMETHASONE, LENALIDOMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00142116	Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia	Phase 2	25	2014-06-02	Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma	RITUXIMAB, THALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00711828	Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma	Phase 2	21	2015-01-27	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia	BORTEZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02898259	Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma	Phase 1/2	19	2021-01-13	B Cell Lymphoma, Lymphoma	IXAZOMIB, LENALIDOMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00566332	Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia	Phase 3	414		Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma	CHLORAMBUCIL, FLUDARABINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 27

See all 27 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials14

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21566092	RESULT	1	PubMed
19015393	RESULT	1	PubMed
18713945	RESULT	1	PubMed
16946304	RESULT	1	PubMed
15284112	RESULT	1	PubMed
42782312	DERIVED	1	PubMed
38235512	DERIVED	1	PubMed
34398557	DERIVED	1	PubMed
34320785	DERIVED	1	PubMed
33448893	DERIVED	1	PubMed

1 to 10 of 14

See all 14 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000432

GET https://conductscience.org/api/diseases/v1/MONDO_0000432/drugs?page=2

API reference For AI assistants